Promus Premier versus Xience V and Taxus Liberte in contemporary United States practice (REWARDS premier registry).
暂无分享,去创建一个
Thomas D. Scott | T. Nazif | R. Torguson | R. Waksman | M. Gaglia | Jiaxiang Gai | D. Steinberg | G. Mishkel | John Wang | A. Tabrizchi | R. Goodroe | Mario Lopez | Wassim Gharib
[1] M. Mamas,et al. Incidence and mechanisms of longitudinal stent deformation associated with Biomatrix, Resolute, Element, and Xience stents: Angiographic and case‐by‐case review of 1,800 PCIs , 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[2] Hyun-Jae Kang,et al. A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness , 2014, Journal of the American College of Cardiology.
[3] J. Ormiston,et al. Stent Longitudinal Strength Assessed Using Point Compression: Insights From a Second-Generation, Clinically Related Bench Test , 2014, Circulation. Cardiovascular interventions.
[4] S. Bangalore,et al. Outcomes With Various Drug-Eluting or Bare Metal Stents in Patients With ST-Segment–Elevation Myocardial Infarction: A Mixed Treatment Comparison Analysis of Trial Level Data From 34 068 Patient-Years of Follow-up From Randomized Trials , 2013, Circulation. Cardiovascular interventions.
[5] T. Ryan,et al. Percutaneous coronary intervention with second-generation paclitaxel-eluting stents versus everolimus-eluting stents in United States contemporary practice (REWARDS TLX Trial). , 2012, The American journal of cardiology.
[6] C. Simonton,et al. Engineering assessment of the longitudinal compression behaviour of contemporary coronary stents. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[7] M. Mamas,et al. Longitudinal stent deformation: insights on mechanisms, treatments and outcomes from the Food and Drug Administration Manufacturer and User Facility Device Experience database. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[8] Deepak L. Bhatt,et al. Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents: A Mixed-Treatment Comparison Analysis of 117 762 Patient-Years of Follow-Up From Randomized Trials , 2012, Circulation.
[9] John A Ormiston,et al. Stent longitudinal integrity bench insights into a clinical problem. , 2011, JACC. Cardiovascular interventions.
[10] P. Smits,et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial). , 2011, Journal of the American College of Cardiology.
[11] Gregg W Stone,et al. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. , 2011, Journal of the American College of Cardiology.
[12] T. Nguyen-Dang,et al. Major stent deformation/pseudofracture of 7 Crown Endeavor/Micro Driver stent platform: incidence and causative factors. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[13] Gregg W Stone,et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. , 2011, Journal of the American College of Cardiology.
[14] G. Stone,et al. Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial). , 2011, The American journal of cardiology.
[15] J. Ormiston,et al. Stent longitudinal flexibility: A comparison of 13 stent designs before and after balloon expansion , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.